Open-label, multicenter, single-arm phase II study (DeCOG-Trial) to further evaluate the efficacy and safety of ipilimumab in patients with cutaneous melanoma and rare subgroups.

Lisa Zimmer, Dirk Schadendorf, Julia-Marianne Vaubel et al.|Journal of Clinical Oncology|2014

Cited by 8